UPDATE 2-U.S. FDA approves AbbVie hepatitis C drug, costs $83,319 for 12 weeks

Dec 19 - U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, and the company said the drug would cost $83,319 for a typical 12-week plan, a bit below its huge selling competitor Solvadi from Gilead Sciences.

1:02am GMT

UPDATE 2-UN chief praises Ebola nurses, pledges support during visit

* Ebola death toll nears 7,000 (Recasts after Sierra Leone visit)

12:42am GMT

AbbVie says newly approved hepatitis C treatment costs $83,319

Dec 19 - An AbbVie Inc spokeswoman on Friday said that the company's newly approved hepatitis C treatment will cost $83,319 for a 12-week course, coming in a bit below the price of competing treatments from Gilead Sciences Inc.

19 Dec 2014

UPDATE 1-Child being observed at Chicago hospital to rule out Ebola

CHICAGO, Dec 19 - A child who arrived in Chicago with a fever was under observation on Friday at a city hospital to rule out the Ebola virus, hospital officials said.

19 Dec 2014

FDA approves Cubists' drug for antibiotic-resistant bacteria

Dec 19 - Cubist Pharmaceutical Inc's drug to treat complicated urinary tract and intra-abdominal infections won U.S. approval on Friday, highlighting the regulator's interest in tackling the growing threat of the so-called superbugs.

19 Dec 2014
GlaxoSmithKline PLC 1,392.00p +0.98%
AstraZeneca PLC 4,565.00p -0.16%
Smith & Nephew PLC 1,089.00p +0.37%


  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.